Company intelligence / Profile preview

Trained Therapeutix Discovery

Oss, Netherlands

Ownership: Private
Development stage: Other

Overview

Preclinical studies demonstrate MTP10-HDL nanobiologic suppresses tumor growth in B16F10 mouse melanoma model via trained immunity induction, with favorable safety in non-human primates; working towards IND filing.

Modalities: Nanobiologic
Industry: Biotech

Drug pipeline

3 assets

RIDE-001

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Trained Therapeutix Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trained Therapeutix Discovery.

Explore the full profile